Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Current Treatment of Younger 1L AML in 2024

Gautam Borthakur

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts